Emergent BioSolutions Stock Forecast
NYSE: EBSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
After hours: 7.02 -0.57%
EBS analyst consensus
Consensus (3 analysts)
none
Avg. price target
$11.00+55.81%
- Strong buy 0
- Buy 2
- Hold 0
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 3 Wall Street analysts covering Emergent BioSolutions (2026-10-08), 2 rate the stock a buy or strong buy, 0 rate it a hold and 1 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $11.00, with a high estimate of $12.00 and a low estimate of $10.00. The average target implies upside of 55.8% from the current price of $7.06.
The spread between the highest and lowest targets is 20.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for EBS.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 2 | 67% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 1 | 33% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $10.00 | +41.64% |
| Average target | $11.00 | +55.81% |
| High target | $12.00 | +69.97% |